SNN-0029
- Generic Name
- SNN-0029
A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 15
- Registration Number
- NCT01999803
- Locations
- 🇧🇪
Philip Van Damme, Leuven, Belgium
🇳🇱Leonard van den Berg, Utrecht, Netherlands
An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 15
- Registration Number
- NCT01384162
- Locations
- 🇧🇪
University Hospital Leuven, Department of Neurology, Leuven, Belgium
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 18
- Registration Number
- NCT00800501
- Locations
- 🇧🇪
University Hospital Leuven, Department of Neurology, Leuven, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath